TY - JOUR
T1 - Antenatal glucocorticoid treatment affects preterm infants' S100B urine concentration in a dose-dependent manner
AU - Sannia, Andrea
AU - Risso, Francesco M.
AU - Serpero, Laura D.
AU - Frulio, Rosanna
AU - Michetti, Fabrizio
AU - Abella, Raul
AU - Frigiola, Alessandro
AU - Giamberti, Alessandro
AU - Gazzolo, Diego
PY - 2010/10
Y1 - 2010/10
N2 - Background: Maternal glucocorticoid (GC) treatment is widely used to prevent lung immaturity in preterm infants. There is growing evidence that GCs may be detrimental to the Central Nervous System (CNS). We investigated whether antenatal GC administration affects CNS function in a dose-dependent manner by measuring urine concentrations of a well-established brain damage marker, S100B. Methods: We conducted a case-control-study in 70 preterm infants (1 GC vs 1 control) whose mothers received a complete GC-course (GC2, n=16), half-course (GC1, n=19), and controls (n=35). At four predetermined time-points, in the first 72. h from birth, we assessed S100B urine concentrations, using a commercially available immunoluminometric assay (Lia-mat Sangtec 100, AB Sangtec Medical, Bromma, Sweden). Data were correlated with primary neonatal outcomes (incidence of respiratory distress syndrome, length of ventilatory support and hospital stay, incidence of intraventricular hemorrhage, adverse 7th day neurological follow-up and neonatal death). Results: S100B in GC2 group at all monitoring time-points was significantly lower (P 0.05) were evident between controls and GC1 group. No significant differences (P >0.05) were shown in primary outcomes between half or complete GC-course treated groups. Conclusion: S100B levels of infants antenatally treated with GCs differed in a dose-dependent manner. Data on primary outcomes suggest that lowering antenatal GC-course may be less detrimental for brain without affecting lung maturation. Further clinical trials are needed to elucidate the low GC-course issue.
AB - Background: Maternal glucocorticoid (GC) treatment is widely used to prevent lung immaturity in preterm infants. There is growing evidence that GCs may be detrimental to the Central Nervous System (CNS). We investigated whether antenatal GC administration affects CNS function in a dose-dependent manner by measuring urine concentrations of a well-established brain damage marker, S100B. Methods: We conducted a case-control-study in 70 preterm infants (1 GC vs 1 control) whose mothers received a complete GC-course (GC2, n=16), half-course (GC1, n=19), and controls (n=35). At four predetermined time-points, in the first 72. h from birth, we assessed S100B urine concentrations, using a commercially available immunoluminometric assay (Lia-mat Sangtec 100, AB Sangtec Medical, Bromma, Sweden). Data were correlated with primary neonatal outcomes (incidence of respiratory distress syndrome, length of ventilatory support and hospital stay, incidence of intraventricular hemorrhage, adverse 7th day neurological follow-up and neonatal death). Results: S100B in GC2 group at all monitoring time-points was significantly lower (P 0.05) were evident between controls and GC1 group. No significant differences (P >0.05) were shown in primary outcomes between half or complete GC-course treated groups. Conclusion: S100B levels of infants antenatally treated with GCs differed in a dose-dependent manner. Data on primary outcomes suggest that lowering antenatal GC-course may be less detrimental for brain without affecting lung maturation. Further clinical trials are needed to elucidate the low GC-course issue.
KW - Glucocorticoids
KW - Prematurity
KW - RDS
KW - S100B protein
KW - Side effects
UR - http://www.scopus.com/inward/record.url?scp=77955053744&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955053744&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2010.05.045
DO - 10.1016/j.cca.2010.05.045
M3 - Article
C2 - 20570670
AN - SCOPUS:77955053744
VL - 411
SP - 1539
EP - 1541
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
SN - 0009-8981
IS - 19-20
ER -